The burgeoning field of radiopharmaceuticals, propelled by the success of treatments like Novartis’s Pluvicto (lutetium Lu 177 vipivotide tetraxetan), is…
Read More

The burgeoning field of radiopharmaceuticals, propelled by the success of treatments like Novartis’s Pluvicto (lutetium Lu 177 vipivotide tetraxetan), is…
Read More
In a significant development for neurodegenerative disease research, 28bio, a biotechnology firm based in Los Angeles, USA, has announced the…
Read More
Chapel Hill, NC – Michelle Itano, the esteemed Editor-in-Chief hailing from the University of North Carolina, Chapel Hill, has unveiled…
Read More